共 50 条
- [41] WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH HR+/HER2-LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN FRANCE, GERMANY, ISRAEL, ITALY, SPAIN, AND THE UNITED STATESVALUE IN HEALTH, 2020, 23 : S476 - S476Mahtani, R.Lewis, K.Lambert, A.Last, M.Mitra, D.Bambrick, C.Kurosky, S.
- [42] Proxalutamide plus endocrine therapy as a combination therapy in women with HR+/HER2-/AR+ metastatic breast cancer: A phase I studyANNALS OF ONCOLOGY, 2023, 34 : S354 - S354Li, H.Jiang, H.Song, G.Ran, R.Wang, J.Wang, X.Huang, J.Feng, J.Zhang, L.Zang, A.Yang, H.Pan, Y.He, X.Donng, M.Tong, Y.Wang, Z.Shao, Z.
- [43] A phase II trial assessing the safety of an alternative dosing schedule of palbociclib (palbo) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC): Alt Dose PalboCANCER RESEARCH, 2020, 80 (04)Krishnamurthy, JairamLuo, JingqinAdemuyiwa, FolusoSuresh, RamaRigden, CaronReardon, TimothyWeilbaecher, KatherineFrith, AshleyRoshal, AnnaTandra, PavanCherian, MathewSumma, TracyThomas, ShanaHernandez-Aya, LeonelPeterson, LindsayMa, Cynthia
- [44] HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2-metastatic breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Shah, Payal DeepakTorres, AlexandraAaron, MeganNarayan, VivekKnollman, Hayley MichelleBradbury, Angela R.DeMichele, AngelaRobson, Mark E.Tung, Nadine M.Domchek, Susan M.
- [45] Real-world treatment patterns and clinical outcomes among patients with HR+/HER2-advanced/metastatic breast cancer receiving palbociclib in Brazil: IRIS studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Simon, PatriciaGuarin, AlexandraJain, AnkitaPiton, LucianaLima, JuliaCarvalho, Carla FabrineNazareth, Felipe
- [46] PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2-early breast cancerCANCER RESEARCH, 2018, 78 (04)Mayer, EricaDeMichele, AngelaGnant, MichaelBarry, WilliamPfeiler, GeorgMetzger, OttoBurstein, HaroldMiller, KathyRastogi, PriyaLoibl, SibylleGoulioti, TheodoraZardavas, DimitriosFesl, ChristianKoehler, MariaHuang-Bartlett, CynthiaHuang, XinPiccart, MartineWiner, EricWolff, Antonio
- [47] Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancerEUROPEAN JOURNAL OF CANCER, 2021, 154 : 11 - 20Yuan, YuanLee, Jin SunYost, Susan E.Frankel, Paul H.Ruel, ChristopherEgelston, Colt A.Guo, WeihuaPadam, SimranTang, AileenMartinez, NormaSchmolze, DanielPresant, CaryEbrahimi, BehnamYeon, ChristinaSedrak, MinaPatel, NikiPortnow, JanaLee, PeterMortimer, Joanne
- [48] Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS studyFUTURE ONCOLOGY, 2021, 18 (03) : 349 - 362Mycock, KatieZhan, LinHart, KieranTaylor-Stokes, GavinMilligan, GaryAtkinson, ChristianMitra, Debanjali
- [49] A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Malorni, LucaCurigliano, GiuseppeMinisini, Alessandro MarcoCinieri, SaverioTondini, CarloArpino, GraziaPavesi, LorenzoMartignetti, AngeloCriscitiello, CarmenPuglisi, FabioPestrin, MartaSanna, GiuseppinaMoretti, EricaRisi, EmanuelaBiagioni, ChiaraBoni, LucaBaldari, DanielaBuyse, Marc E.Biganzoli, LauraDi Leo, Angelo
- [50] Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2-metastatic breast cancer: WJOG11418B NEWFLAME trialCANCER RESEARCH, 2021, 81 (04)Masuda, JunTsurutani, JunjiMasuda, NorikazuTanabe, YukoIwasa, TsutomuTakahashi, MasatoFutamura, ManabuMatsumoto, KojiAogi, KenjiroIwata, HirojiHosonaga, MariMukohara, ToruYoshimura, KenichiTakano, Toshimi